ClinicalTrials.gg

Program

dexibuprofen

Also written as “Dexibuprofen”, “S-Ibuprofen Gel 5%” and “S-Ibuprofen”.

Its studies are mostly in Contusions · Acute Pain · Osteoarthritis, Hip, led by 3 companies.

Furthest: phase 4, since Oct 25, 20266 company-led studies, 1 open or runningNext primary completion: Jun 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aponia Laboratories21 open or runningphase 3since Oct 25, 2026Feb 20, 2019Jun 2027phase 3 · NCT07930559
Apsen Farmaceutica20 open or runningphase 1since Nov 1, 2016Nov 1, 2016none ahead
Gebro Pharma20 open or runningphase 4since Feb 9, 2010Mar 1, 2007none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 1, 2007First study: phase 1 study in Drug InteractionsNew to Gebro PharmaGebro Pharma · NCT00442585 · 72 enrolled · Austria
  2. Feb 9, 2010Phase 4 study in Osteoarthritis, HipGebro Pharma · NCT01066676 · 482 enrolled · Austria
  3. Nov 1, 2016Apsen Farmaceutica's first studies: 2 phase 1 studies in Healthy VolunteersNew to Apsen FarmaceuticaApsen Farmaceutica · NCT02956525, NCT02956512
  4. Feb 20, 2019Aponia Laboratories's first study: phase 2 study in Acute PainNew to Aponia LaboratoriesAponia Laboratories · NCT03852459 · 251 enrolled · United States
  5. Oct 25, 2026Phase 3 study in ContusionsPhase 3 reachedAponia Laboratories · NCT07930559 · 240 planned · United States, Germany

Ahead

  1. Jun 2027Primary completion: phase 3 study in ContusionsAponia Laboratories · NCT07930559

TargetBeta

PTGS1 →PTGS2 →read by rule
“Cyclooxygenase inhibitor”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
AcetaminophenruleJohnson & Johnsonphase 4136
IbuprofenrulePfizerphase 4113
AspirinruleBayerphase 484
dexketoprofenruleMenarini Groupphase 48
SulfasalazineruleBristol-Myers Squibbphase 47
BenzydamineruleAngelini Pharmaphase 44
DipyroneruleHypera Pharmaphase 44
PiroxicamruleTaisho Pharmaceuticalphase 44
FlurbiprofenruleGlaxoSmithKlinephase 312

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07930559Contusions · United States, Germany3RecruitingAponia LaboratoriesJun 2027240
NCT03852459Acute Pain · United States2CompletedAponia LaboratoriesApr 4, 2019251
NCT02956525Healthy Volunteers · Brazil1CompletedApsen FarmaceuticaJul 1, 201852
NCT02956512Healthy Volunteers · Brazil1CompletedApsen FarmaceuticaJul 12, 201952
NCT01066676Osteoarthritis, Hip · Austria4CompletedGebro PharmaJun 2012482
NCT00442585Drug Interactions · Austria1CompletedGebro Pharma72

How it is read

Names in the registry

  • “Dexibuprofen”, 3 entries
  • “S-Ibuprofen Gel 5%”, 1 entry
  • “S-Ibuprofen”, 1 entry
  • “S(+)-ibuprofen”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.